Transaction in Own Shares | 27-May-2025 | 07:00 | RNS |
positive CHMP opinion on Blenrep in EU | 23-May-2025 | 12:16 | RNS |
Transaction in Own Shares | 23-May-2025 | 07:00 | RNS |
FDA approves Nucala COPD indication | 23-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 22-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 21-May-2025 | 07:00 | RNS |
Director/PDMR Shareholding | 20-May-2025 | 15:30 | RNS |
Transaction in Own Shares | 20-May-2025 | 07:00 | RNS |
Blenrep for 2L+ multiple myeloma approved in Japan | 19-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 19-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 16-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 15-May-2025 | 07:00 | RNS |
GSK to acquire efimosfermin | 14-May-2025 | 07:00 | RNS |
Transaction in Own Shares | 14-May-2025 | 07:00 | RNS |
Director/PDMR Shareholding | 13-May-2025 | 15:30 | RNS |
Currency | UK Pounds |
Share Price | 1,448.00p |
Change Today | 22.50p |
% Change | 1.58 % |
52 Week High | 1,774.50 |
52 Week Low | 1,264.00 |
Volume | 7,237,685 |
Shares Issued | 4,100.23m |
Market Cap | £59,371m |
Beta | 0.00 |
RiskGrade | 129 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 4 |
Buy | 2 |
Neutral | 14 |
Sell | 3 |
Strong Sell | 1 |
Total | 24 |
Latest | Previous | |
---|---|---|
Q1 | Q4 | |
Ex-Div | 15-May-25 | 20-Feb-25 |
Paid | 10-Jul-25 | 10-Apr-25 |
Amount | 16.00p | 16.00p |
Time | Volume / Share Price |
16:05 | 0 @ 1,451.00p |
16:01 | 1 @ 1,452.00p |
15:52 | 1 @ 1,454.00p |
15:13 | 5 @ 1,452.50p |
14:56 | 10 @ 1,453.00p |
You are here: research